Robert Flisiak

Robert Flisiak is a **Professor** at the **Department of Infectious Diseases and Hepatology**, part of the **Faculty of Medicine** at the **Medical University of Bialystok**. His research focuses on viral hepatitis, antiviral therapies, and infectious disease management, with a strong emphasis on hepatitis C treatment strategies, SARS-CoV-2 management, and public health policy. He has contributed to clinical guidelines for SARS-CoV-2 and chronic hepatitis infections. Recent work includes studies on therapy adherence in hepatitis C, post-COVID-19 pulmonary sequelae, and the efficacy of direct-acting antivirals in diverse populations such as HIV/HCV coinfected patients, the elderly, and cancer patients. His research also addresses liver pathology (e.g., steatosis, fibrosis) and viral infections like tick-borne encephalitis.

Key research interests include:

• Hepatitis C treatment optimization
• Antiviral drug efficacy and safety
• Post-infectious complications (e.g., long-COVID, liver fibrosis)
• Infectious disease guidelines and public health policy

Publications highlight real-world applications of antivirals, including their use in marginalized groups (e.g., Ukrainian refugees) and underrepresented populations (elderly, cancer patients). Collaborations span international studies on respiratory infections and pandemic-related cardiovascular risks.

No scientific awards are explicitly listed in the provided texts. Advising and grants remain unspecified, though his active research output suggests involvement in academic teams and clinical trials.